CorMedix Inc

CRMD Healthcare Biotechnology

CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.

7.26 0.20 −2.68%
Market cap
$581.5M
P/E
3.0×
Fwd P/E
16.5×
Dividend yield
—
F-score
n/a
Altman Z
2.15
Beneish M
12.80
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— — — 4
ROE
75.08% 66.56% 65.59% 54.93%
ROA
39.23% 34.51% 37.51% 32.36%
ROIC
14.02% 23.38% 29.97% 38.84%
Return on Tangible Assets
124.77% 82.04% 69.49% 62.18%
Average Days of Receivables
270.08 200.51 141.24 127.37
Free Cash Flow per Share
0.98 2.40 2.45 3.19
Free Cash Flow
74.42 172.79 194.71 250.42
Other line items

Show all line items

Columns are period end dates